TaiwanPlus Curated Its First Film Festival to Showcase 10 Taiwanese Films Including Ang Lee’s Early Classics
1.12.2021 10:39:00 EET | Business Wire | Press release
TaiwanPlus, a new global English-language video streaming service, has launched a Taiwan Cinema program with a selection of ten films that exemplify the diversity of Taiwan’s culture, peoples, and history. The most prominent collection is Ang Lee’s 'Father Knows Best' trilogy. Notably, this is the first time the films are available to be streamed online together. Director Lee’s strength in bringing together family members to create tension and tender comedic moments shine in this trio of PUSHING HANDS (1991), EAT DRINK MAN WOMAN (1994), and THE WEDDING BANQUET (1993).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211130006205/en/
Taiwan+ Film Festival 2021 is on! (Photo: Business Wire)
Renowned actor Sihung Lung acts as the consummate traditional Taiwanese father in roles that evoke the sweet bitterness of an aging man trying to bring each casts’ family together. Hailed for their unrestrained portrayals of Eastern family dynamics, the collection is available for free until December 31, 2021 to global viewers outside of the United States, Canada, Mexico, Germany, and France at TaiwanPlus.com via the website’s new Cinema section and downloadable TaiwanPlus mobile app.
In addition, seven other films will be presented until December 31, 2021 that will take viewers back to some of Taiwan’s greatest films outside of the Taiwan New Cinema Wave. “Movies are the best way to convey culture and emotions. Through these ten films of different eras and themes, we provide the audience a window into Taiwan’s culture and diversity.” says Joanne Tsai, TaiwanPlus CEO.
In addition to Ang Lee’s renowned films, the program is showcasing films directed by Chung Mong-hong, who recently won Best Narrative Feature and Best Original Screenplay for THE FALLS (2021) at this year's Golden Horse Awards. The After Death duo that brings us to edgier contemporary Taiwanese films that dare to dive into darker narratives. THE FOURTH PORTRAIT (2010) follows the story of a son left behind after the death of his father while in SOUL (2013), the mysterious collapse of a young chef leads to a terrifying spiritual possession in the mountains.
A trio of restored films include two cult favorite black and white films from the Taiwan Hollywood era of the 1960s-- THE FANTASY OF DEER WARRIOR (1961) and VENGEANCE OF THE PHOENIX SISTERS (1968) along with WHEEL OF LIFE (1983), an anthology helmed by King Hu that features three main characters reincarnating into the same twisted love triangle in each segment.
Rounding out the series are two documentaries. In SMALL TALK (2016) by Huang Hui-chen, a 20 year film in the making where the filmmaker attempts to confront and reconcile painful past memories with her mother, a lesbian Taoist priestess. Meanwhile, in ARCHIVING TIME (2019), viewers follow a group of film preservation staff from the Taiwan Film and Audiovisual Institute as they work to preserve crumbling reels of film the world has yet to see.
Watch Free @https://tw.plus/twxgh
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211130006205/en/
Contact information
Vicky Hsu
pr@taiwanplus.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
